Bicalutamide 50 mg tablet compression: feed frame torque, particle size overlap, and dissolution acceptance criteria

The 4-Amino-2-(trifluoromethyl)benzonitrile stream entering the pharmaceutical manufacturing suite is not tableted directly but is charged as the penultimate pharma-grade intermediate for bicalutamide drug substance via acylation with 3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanoic acid. The nitrile intermediate, identified as CAS 654-70-6, is controlled at HPLC assay of not less than 98.0% area, with residual water, residual solvent, and related-substance limits applied before the final coupling step. The resulting bicalutamide is recrystallized, dried, and either micronized or wet-granulated before tablet manufacture. In the immediate-release 50 mg tablet route, the active fraction is first preblended with lactose monohydrate as the main diluent at approximately 70–80% w/w, sodium starch glycolate as disintegrant at 2–5% w/w, and povidone K30 as binder at 2–4% w/w; magnesium stearate is added last at 0.5–1.5% w/w to avoid over-lubrication, which can reduce tablet hardness and retard dissolution. Micronized active with a D90 below 20 µm is preferred for dissolution performance, but this particle size fraction creates a processing conflict by increasing interparticulate adhesion, lowering bulk density, and producing feed frame torque fluctuations on the rotary tablet press. The 16-station instrumented press is typically operated at pre-compression force of 2–4 kN and main compression force of 8–18 kN, with turret speed limited to 30–60 rpm because higher speeds amplify weight variation from fines segregation. In-process controls include individual tablet weight, hardness, friability according to USP <1216>, disintegration according to USP <701>, and dose-unit uniformity according to USP <905>. Dissolution is tested under USP <711> in surfactant-containing aqueous medium at 37 ± 0.5 °C, with acceptance criteria set by the finished product monograph. The terminal product is a film-coated immediate-release tablet for once-daily oral administration, with coating weight gain controlled in the range of 2–4% w/w to maintain disintegration and dissolution performance.

In capsule-oriented manufacturing lines where the same 50 mg strength is filled into hard gelatin or HPMC shells, the control emphasis shifts from compression force and feed frame behaviour to plug formation, powder bed uniformity, and shell moisture exchange. The wet granulation route for capsule filling typically uses the active substance, lactose monohydrate or microcrystalline cellulose as the diluent at 70–90% w/w, croscarmellose sodium or sodium starch glycolate as disintegrant at 0–3% w/w, and magnesium stearate at 0.25–1.0% w/w. The granulate is dried to a loss on drying of 1.5–2.5%, then screened through a 0.8–1.0 mm mill before encapsulation. On dosator or tamping-pin type capsule fillers, tamping pin compression depth and spring pressure control plug density, while powder bed height is adjusted to hold fill weight within ±5% of the target. The filling suite is maintained below 45% relative humidity because hard gelatin shells become brittle below 30% relative humidity and tacky above 55% relative humidity; HPMC shells tolerate a slightly broader range but still require moisture mapping during seasonal production. Weight variation is assessed by USP <905>, dissolution by USP <711>, and moisture by USP <731>; aldehyde-containing packaging materials must be excluded to avoid gelatin shell crosslinking that slows dissolution. The terminal product is a capsule presentation with the same oral dose as the film-coated tablet, intended for patients with swallowing difficulties or where regional prescribing preference requires capsule administration.

What limits the use of 4-amino-2-(trifluoromethyl)benzonitrile in injectable-grade synthesis?

Injectable formulations derived from this nitrile intermediate depend on first converting the starting amine to the final amide drug substance and then applying parenteral-grade purification that removes residual nitrile, unreacted amine, and process solvents to limits substantially tighter than oral grades. The commercial pathway is built around the same coupling reaction used for oral solid dosage, but the purified bicalutamide is subjected to additional recrystallization, carbon treatment, and solvent exchange because the injection route is governed by USP <71> sterility, USP <85> bacterial endotoxin, USP <788> particulate matter, and USP <790> visible particulate release criteria. Residual solvent control is anchored to ICH Q3C, with class 2 solvents such as dichloromethane and methanol limited to their permitted daily exposure values; elemental impurities follow ICH Q3D and USP <232>/<233>. The active is lipophilic and practically insoluble in water at neutral pH, so a true aqueous injectable requires either a co-solvent system such as polyethylene glycol/ethanol/water, a cyclodextrin inclusion complex, or a lyophilized cake with mannitol or trehalose as the crystalline bulking agent. For lyophilized presentations, the bicalutamide is dissolved in a solvent system that may include tert-butanol or ethanol, filtered through a 0.22 µm PVDF membrane, filled into glass vials, and freeze-dried using a cycle with an annealing step to avoid high residual solvent in the cake. Terminal steam sterilization at 121 °C for 15 minutes may be tested but cannot be assumed suitable because the amide and nitrile groups are susceptible to hydrolytic degradation under sustained moisture and heat; published data for this specific configuration is limited, and aseptic filtration remains the default for formulations that fail terminal sterilization stability. The terminal product is an investigational injectable or lyophilized vial intended for parenteral administration, with batch release necessarily including osmolality, pH, sterility, endotoxin, particulate matter, residual solvent, and elemental impurity testing.

If the intended terminal presentation is an oral granule in a sachet rather than a coated tablet or capsule, the manufacturing route switches to wet granulation followed by fluid-bed drying to produce discrete, free-flowing granules in the 125–500 µm size range. A representative sachet formulation for a 50 mg or 150 mg dose contains the active substance, mannitol or lactose monohydrate as the bulk diluent, hydroxypropyl cellulose or povidone as the binder at 2–4% w/w, and colloidal silicon dioxide as glidant at 0.1–0.5% w/w; sweetener and flavour are added only where the clinical formulation and regional regulatory filing permit. Granulation is carried out in a high-shear mixer with impeller and chopper speeds controlled to avoid over-granulation that would generate hard lumps above 1 mm; the wet mass is discharged through a 1.0–1.5 mm screen and dried in a fluid-bed dryer at an inlet air temperature below 60 °C because the active and binder can form heat-labile agglomerates at higher temperature. After drying to loss on drying of 1.0–2.0% w/w, the granules are sieved and filled into aluminium foil sachets under nitrogen purge; desiccant is included when the sachet laminate water vapour transmission rate exceeds 0.1 g/m²/day. Unit-dose uniformity for sachets is tested according to USP <905> if the container is a unit-dose package, while dissolution follows USP <711> using a paddle or basket apparatus after the sachet content is dispersed in the specified medium. The terminal product is an oral granule for suspension or direct administration, suitable for dose-banded clinical trials and for patients who cannot swallow conventional tablets.

When a 150 mg monotherapy tablet moves from immediate release to sustained release, matrix selection becomes the rate-limiting variable

Although bicalutamide has a long plasma half-life and is conventionally given as an immediate-release 150 mg tablet, sustained-release development work evaluates hypromellose matrix systems to modulate pre-systemic exposure or reduce peak-related adverse events in selected patient subsets. In such a matrix tablet, the active is dispersed at 5–10% w/w of the tablet mass in hypromellose USP substitution type 2208 or 2910 at 20–40% w/w, with lactose monohydrate or dibasic calcium phosphate dihydrate as filler and magnesium stearate at 0.5–1.5% w/w as lubricant. The viscosity grade of the polymer, expressed as apparent viscosity of a 2% aqueous solution, controls the rate of gel layer formation and erosion; K4M and K100M grades are common reference points, with higher viscosity grades retarding release over a longer time. Direct compression is feasible only when the polymer is coarse or spray-dried; otherwise dry granulation with roller compaction is used to prevent segregation and improve flow. Compression force must be monitored with a force-displacement system because excessive compression reduces matrix porosity below the percolation threshold and slows dissolution beyond the acceptance range; too low a force produces capping and erratic erosion. Dissolution testing in a paddle apparatus at 50 rpm typically samples at 1, 4, 8, 12, and 24 hours to characterise the release profile, but published data for this specific configuration is limited, and each formulation requires ICH Q1A(R2) stability verification before commercialisation. The terminal product is a sustained-release tablet designed for once-daily oral administration, with release rate determined by polymer hydration rather than immediate disintegration.

Below the limit of conventional powder flow testing, micronization of the active via a fluid energy mill becomes the critical step for achieving the particle size range required in immediate-release oral and injectable-suspension formulations. The fluid energy mill uses compressed air or nitrogen at controlled grinding pressure; the feed rate is adjusted so that the mill chamber temperature stays below 40–50 °C because the nitrile intermediate and the final amide both develop static charge and agglomerates under dry grinding. After micronization, the active is blended concurrently with colloidal silicon dioxide or pre-blended with a portion of the filler to reduce surface free energy and improve subsequent flow. Particle size is measured by laser diffraction according to USP <429> and is expressed as D10, D50, and D90; a tight span value is preferred over a single D90 because fine tails and coarse tails influence dissolution and segregation differently. Process control includes periodic sampling at the mill discharge to verify that the D50 remains within the validated limit and that no oversized particles appear from nozzle wear or filter breakthrough. For injectable nanosuspension or microsphere development, further wet milling or high-pressure homogenization may be required after micronization; published data for this specific configuration is limited, and the operational boundary is defined by particle aggregation rather than chemical instability. The terminal output of this application segment is the size-controlled active intermediate that supplies the tablet, capsule, granule, or parenteral formulation route.

Analytical transfer, cleaning validation, and carry-over control in multi-product oral solid dosage facilities

The final downstream application is not a dosage form but the analytical and cleaning framework required when the nitrile intermediate and its bicalutamide downstream product are handled in shared manufacturing suites. HPLC assay and related substance methods for the intermediate are developed on C18 or phenyl columns with ultraviolet detection in the range of 220–254 nm; the method must resolve the starting amine from the acid coupling partner and from the final amide, with quantification thresholds set according to the applicable ICH Q3B drug product reporting threshold for related substances. Cleaning validation is anchored to 21 CFR 211.67 and 21 CFR 211.67(b), with carry-over acceptance limits derived from the maximum allowable carryover calculation based on the therapeutic daily dose and batch size; swab and rinse sampling are performed after each campaign, with validated limits expressed as micrograms of residue per swab and total residue per equipment train. Personnel exposure and cross-contamination are managed under a health-based exposure limit, with HPLC detection used to confirm that the intermediate is absent in the next product at or below the pre-approved carry-over level. This segment is essential for contract development and manufacturing organisations that handle cytotoxic or hormonally active substances in the same facility, because the antiandrogen downstream product is a hormonally active compound subject to dedicated cleaning and segregation controls. The terminal deliverable is a release package, cleaning record, and analytical method transfer report that links the intermediate to each finished oral or injectable product.